Stock listing

Apellis Pharmaceuticals, Inc.

Selected listing: 1JK · DUS · EUR · DE

Apellis Pharmaceuticals, Inc. (Dusseldorf:1JK), Health Technology. Latest release Sep 17, 2026: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal…

1JK:DUSEURDEUpdated October 4, 2026

Ticker: Dusseldorf:1JK
Asset type: Stock
Sector: Health Technology
Industry: Pharmaceuticals: Major
Exchange: Dusseldorf
Currency: EUR

Latest news from Apellis Pharmaceuticals, Inc.

Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN

September 17, 2026

Canada’s Drug Agency Issues Positive Reimbursement Recommendation for EMPAVELI® (pegcetacoplan) for the Treatment of C3G and Primary IC-MPGN

July 9, 2026

Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

March 30, 2026

Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors

March 1, 2026

Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

February 24, 2026

All Apellis Pharmaceuticals, Inc. news →

Events

Replays

Apellis Pharmaceuticals, Inc. (APLS) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 08:30 AM ET
Watch
Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call
Thu, Oct 30, 2025 · 08:30 AM ET
Watch
Apellis Pharmaceuticals, Inc. (APLS) Q2 2025 Earnings Call
Thu, Jul 31, 2025 · 08:30 AM ET
Watch

Research Apellis Pharmaceuticals, Inc.

Apellis Pharmaceuticals, Inc. company profile

View the public company page for Apellis Pharmaceuticals, Inc. on 6ix.

Apellis Pharmaceuticals, Inc. news

Read company news and market updates connected to Apellis Pharmaceuticals, Inc..

Apellis Pharmaceuticals, Inc. investor events

Find investor webinars, events, and replay context for Apellis Pharmaceuticals, Inc..